HLA-C and neoplasm: Neoantigens arise from somatic mutations and are presented on tumor cell surfaces by major histocompatibility complex (MHC) molecules, enabling cytotoxic T lymphocytes (CTLs) to target and eliminate tumor cells [9, 11, 12].